SERG Technologies, a London-based company that develops devices to diagnose and monitor Parkinson’s disease, announced that it has raised £1.6M in funding.
The Imperial College London spin-out secured investment from Mercia, Velocity Partners, Newable, the Imperial College Innovation Fund, a leading Japanese corporation, and private investors.
The company will use the funds to expand its team and accelerate technology development, as it plans to launch its NuRO-connected platform in the UK and US
What does SERG Technologies solve?
Around 400M people globally are affected by NDMDs (Neurodegenerative Movement Disorders).
Parkinson’s disease, which affects around 10M people worldwide, is the fastest growing neurological condition and typically causes symptoms including stiffness of the limbs, tremors, and slowness of movement.
Dr. Christos Kapatos, co-founder and CEO of SERG Technologies, comments, “Our vision is to enable people with Parkinson’s and other neurodegenerative diseases and movement disorders to live healthier lives. NuRO could give patients and clinicians a much clearer picture of their condition, enabling treatment to be tuned accurately as needed. We’re excited to continue our work with leading hospitals and patient groups and to bring our technology to market.”
Treating Parkinson’s with AI
Founded by Dr. Ravi Vaidyanathan and Dr. Samuel Wilson, SERG’s technology, NuRO, enables remote and patient-specific assessment of all motor symptoms.
It uses AI to provide patients, clinicians, and health systems with the necessary data and actionable insights to close the loop between monitoring and management of the disease.
NuRO is a non-invasive and non-pharmaceutical treatment solution that targets the plasticity of the brain, training it to regain control and delivering long-term improvement.
Rob Bennett, asset manager, Mercia, says, “One of the current frustrations in treating Parkinson’s disease is that patients are assessed on their symptoms, with a lack of objective data. While there are powerful drugs that can ease the symptoms, it is difficult for doctors to get the right dose or develop better treatments because there is no effective ‘yardstick’ to measure patients’ conditions. SERG’s technology could transform treatment by unlocking insights into the disease by providing real-time, continuous feedback.”
Dr. Brijesh Roy, Seed Investment Manager at Imperial College London, says, “SERG has identified a promising technical solution to the substantial challenge of improving disease management for the UK’s Parkinson’s patients. This funding round allows the company to gather important data and progress towards a commercial product launch.”
Dimitris Kalavros-Gousiou, Co-founder & Partner at Velocity.Partners VC, says, “Having followed SERG’s journey since the start, we are happy to witness its next product development phase unfolding, bringing its product closer to commercialization, with the successful closing of the current -seed- round. We firmly believe in SERG’s mission and its ability to deliver on its promise, which could positively affect and improve the lives of more than 10 million people worldwide.”
